Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study

References

• Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006; 333:15.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42:200–9.
   PubMed Web of Science ®Google Scholar
• Sackett DL. Compliance in health care. Baltimore, John Hopkins University Press: 1979.
   Google Scholar
• Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld FC, Dougados M, EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 15;59:762–84.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54:1401–9.
   PubMed Web of Science ®Google Scholar
• Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rodevand E, Nossent JC. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Scand J Rheumatol 2009; 19:1–6.
   Google Scholar
• Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39:975–81.
   PubMed Web of Science ®Google Scholar
• Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol 2000;27:1864–71.
   PubMed Web of Science ®Google Scholar
• Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000; 27:1139–47.
   PubMedGoogle Scholar
• Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003; 30:2325–9.
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50:105–16.
   PubMed Web of Science ®Google Scholar
• Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9(6 Suppl):S136–43.
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45(10 Supl 2):S66–76.
   PubMedGoogle Scholar
• Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum;38:396-402.
   PubMedGoogle Scholar
• de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30:44–54.
   PubMed Web of Science ®Google Scholar
• Ortendahl M, Holmes T, Schettler JD, Fries JF. The methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol 2002; 29:2084–91.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22–9.
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28:437–43.
   PubMed Web of Science ®Google Scholar
• Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 2009;29:411-5.
   PubMed Web of Science ®Google Scholar
• Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46:263–8.
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case–control study. Br J Cancer 2005; 14;92:594–6.
   PubMedGoogle Scholar
• Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 2;88:1687–92.
   PubMed Web of Science ®Google Scholar
• Guidelines for ATC classification and DDD assignment, 5th edn. Oslo, Norway: World Health Organization, 2002.
   Google Scholar
• Introduction to drug utilization research. Oslo, Norway: World Health Organization, 2003.
   Google Scholar
• Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS, Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish database (DANBIO). Scand J Rheumatol 2005; 34:40–4.
   PubMed Web of Science ®Google Scholar
• Christiansen JU, Maruard CD, Nielsen HC. LABKA. A real-time computer system for the clinical laboratory. Scand J Clin Lab Invest Suppl 1989;194:57–61.
   PubMedGoogle Scholar
• Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991; 34:1065–8.
   PubMed Web of Science ®Google Scholar
• Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004; 34:423–6.
   PubMed Web of Science ®Google Scholar
• Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiol Drug Saf 2006; 15:587–93.
   PubMedGoogle Scholar
• Bernatsky S, Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging 2008;25:879–84.
   PubMed Web of Science ®Google Scholar
• Bring JHow to standardize regression coefficients. Am Stat 1994;48:209–11.
   Web of Science ®Google Scholar
• Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006;15:11–17.
   Google Scholar
• Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J Rheumatol 2002;29:261–6.
   PubMed Web of Science ®Google Scholar
• Ideguchi H, Ohno S, Ishigatsubo Y. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis. J Clin Rheumatol 2007; 13:73–8.
   PubMedGoogle Scholar
• Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64:207–11.
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15:565–74; discussion 575–7.
   PubMed Web of Science ®Google Scholar
• Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40:1280–8.
   PubMed Web of Science ®Google Scholar
• Yazici Y, Erkan D, Harrison MJ, Nikolov NP, Paget SA. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol 2005; 40:517–20.
   Google Scholar
• Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003; 62:482–6.
   PubMed Web of Science ®Google Scholar
• Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:723–31.
   PubMedGoogle Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• Owen SG, Friesen WT, Roberts MS, Flux W. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol 1985; 24:313–20.
   PubMedGoogle Scholar
• Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 2008; 4:269–86.
   PubMedGoogle Scholar
• DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007; 45:521–8.
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the ‘anchor drug’ for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S179–85.
   Google Scholar
• Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66:iii56–60.
   PubMed Web of Science ®Google Scholar